NYSE$TEVA

Teva Pharmaceutical Industries ADR · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Reported growth in Q4 and full year 2023, driven by innovative brands and strategic collaborations.

Teva Pharmaceutical Industries Ltd. reported a strong Q4 2023, with revenues of $4.5 billion, a 15% increase compared to Q4 2022. GAAP diluted earnings per share were $0.41, and non-GAAP diluted EPS was $1.00. The company's growth was driven by an upfront payment from an anti-TL1A asset collaboration, sale of product rights in Europe, and higher revenues from generic products and AUSTEDO.

  • Revenues increased by 15% to $4.5 billion, driven by upfront payments and innovative products.
  • GAAP diluted EPS reached $0.41, while non-GAAP diluted EPS was $1.00.
  • Gross profit margin improved to 54.2%, due to upfront payments and product mix.
  • The company's 'Pivot to Growth' strategy is progressing, focusing on growth engines and innovation.

Headline financials

Total Revenue

$4.46B

Previous: $3.88B+14.8%
EPS (adj)

$1.00

Previous: $0.71+40.8%
Capital Expenditures

-$119M

Previous: $142M-183.8%
Free Cash Flow

$1.49B

Previous: $1.14B+30.4%
Net Income

$465M

Previous: -$1.22B+138.1%
Operating Income

$755M

Previous: -$855M+188.3%
Gross Profit

$2.42B

Previous: $1.77B+36.4%
R&D Expense

$227M

No prior period
Stock-Based Comp

$28M

Previous: $36M-22.2%

Revenue & EPS history

Teva · Revenue · Quarterly

$4.46B

Q4 2023+14.8%vs Q4 2022
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

Teva · $1.85B total across 3 segments · Q3 2023

  • Europe
    $1.15B+7.2%
  • International Markets
    $485M+2.1%
  • Other Activities
    $217M

Forward guidance

Teva provided its 2024 outlook, including revenue expectations of $15.7-$16.3 billion and non-GAAP diluted EPS of $2.20-$2.50.

Tailwinds

  • Revenues of $15.7 – $16.3 billion
  • AUSTEDO revenues of ~$1,500 million
  • AJOVY revenues of ~$500 million
  • UZEDY revenues of ~$80 million
  • COPAXONE revenues of ~$400 million

Headwinds

  • Operating Income of $4.0 – $4.5
  • Adjusted EBITDA of $4.5 – $5.0
  • Finance Expenses of ~$1,000 million
  • Tax Rate of 14% – 17%
  • Free Cash Flow of $1.7 - $2.0

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+0.3%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+0.7%

Avg return

30 days after

51%

38 / 74 earnings

Positive

+27.1%

Q2 2022

Best reaction

-34.1%

Q2 2017

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.1%+11.9%+11.7%
Q4 2025+2.1%+9.2%+4.1%
Q3 2025+20.4%+18.6%+39.1%
Q2 2025+1.8%-5.1%+11.1%
Q1 2025+8.9%+11.4%+10.2%
Q4 2024-13.9%-19.4%-23.5%
Q3 2024-6.8%-7.5%-7.7%
Q2 2024+6.9%+1.6%+15.0%
Q1 2024+14.7%+21.0%+20.6%
Q4 2023+6.2%+5.5%+15.1%
Q3 2023-3.0%-2.4%+8.6%
Q2 2023+15.4%+16.2%+18.7%
Q1 2023-9.8%-11.3%-19.5%
Q4 2022-9.8%-5.4%-16.3%
Q3 2022-3.3%+3.7%-1.1%
Q2 2022+27.1%+30.5%+37.6%
Q1 2022-2.3%-8.1%+11.6%
Q4 2021+6.3%+2.8%-9.8%
Q3 2021-7.0%-1.7%-9.6%
Q2 2021+8.6%+10.4%+4.8%
Q1 2021+2.6%+4.2%+0.3%
Q4 2020-11.8%-13.2%-15.8%
Q3 2020-1.0%+4.5%+11.6%
Q2 2020+3.0%+0.6%-22.1%
Q1 2020+7.7%+9.0%+22.5%
Q4 2019+1.9%-0.9%-31.9%
Q3 2019+14.8%+18.6%+22.5%
Q2 2019+3.3%-0.6%-0.7%
Q1 2019-0.3%-4.1%-43.2%
Q4 2018-9.6%-6.0%-13.7%
Q3 2018+13.1%+15.6%+7.8%
Q2 2018-7.1%-2.5%-4.0%
Q1 2018-4.1%+1.6%+17.7%
Q4 2017-10.7%-11.2%-8.0%
Q3 2017-18.7%-16.6%+8.8%
Q2 2017-34.1%-16.2%-39.4%
Q1 2017+1.7%+1.3%-3.6%
Q4 2016+8.4%+9.4%+6.7%
Q3 2016-7.2%-6.0%-10.5%
Q2 2016+1.2%-6.2%-8.8%
Q1 2016+5.2%+1.7%+10.8%
Q4 2015-2.0%
Q3 2015-5.1%
Q2 2015-2.6%
Q1 2015+0.1%
Q3 2014+3.6%
Q4 2014+2.0%
Q2 2014-1.6%
Q1 2014+2.0%
Q4 2013-1.9%
Q3 2013-1.5%
Q2 2013-2.0%
Q1 2013+1.0%
Q4 2012+1.4%
Q3 2012+2.6%
Q2 2012-3.3%
Q1 2012-5.4%
Q4 2011+2.5%
Q3 2011+7.0%
Q2 2011+1.9%
Q1 2011+5.6%
Q4 2010+0.4%
Q3 2010+0.3%
Q2 2010-3.4%
Q1 2010+0.9%
Q4 2007+1.2%
Q4 2009+1.2%
Q3 2008-1.4%
Q3 2009-1.4%
Q2 2008-0.8%
Q2 2009-0.8%
Q1 2009-0.6%
Q1 2008-0.6%
Q4 2008-0.6%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro